Paradigm Biopharmaceuticals Ltd (ASX:PAR) CEO Marco Polizzi speaks with Proactive about achieving the primary endpoint in the company’s PARA_OA_008 Synovial Fluid Biomarker Phase 2 clinical trial, assessing the effect of injectable Pentosan Polysulfate Sodium (iPPS) on osteoarthritis (OA) biomarkers over time. Polizzi recaps the trial design, discusses the separate canine study and gives an update on the global phase 3 trial in osteoarthritis.
Paradigm Biopharmaceuticals hails positive results from Phase 2 osteoarthritis trial
